Quantum-first: Safety By Treatment (tx) Phase And By Age Innewly Diagnosed (nd) Patients With Fms-like Tyrosine Kinase 3

In QuANTUM-First, infections and cytopenias associated with Q were observed in all phases. Fatal infectionswere more common with Q in IND & CONS but not in CONT. Rates of prolonged QTcF >500 ms were lowoverall, occurring mostly in IND & CONS, not in CONT with Q. The incidence, nature, and severity of non-GVHDTEAEs reported after resuming Q were consistent with the overall Q safety profile. Pts ≥60 yrs had higherTESAEs and TEAEs with fatal outcome (including early death) vs younger pts in both arms. Q safety profile inacross Tx phases and age grps supports an overall positive benefit/risk.Keywords: Flt3-ITD, Safety, AML

The phase 3 QuANTUM-First study (NCT02668653) showed that in nd FLT3-ITD+ AML pts, adding the oral,highly potent, selective, type 2 FLT3 inhibitor quizartinib (Q) to standard chemotherapy (CTx) ± allogeneichematopoietic cell transplantation (allo-HCT), followed by Q or placebo (P) monotherapy for up to 3 years(yrs), decreased the relative risk of death by 22.4% vs P, with a generally manageable safety profile (PMID:37116523).

https://clin.larvol.com/abstract-detail/EHA 2024/70978432

Quantum-first: Safety By Treatment (tx) Phase And By Age Innewly Diagnosed (nd) Patients With Fms-like Tyrosine Kinase 3–internal Tandem Duplication (